- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05495139
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
A Small-Sample-Size Clinical Study to Evaluate the Effectiveness and Safety of the Gastric Bypass Stent System in Treatment of Patients With Nonalcoholic Fatty Liver Disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ziru Liu
- Phone Number: 0571-86702039
- Email: lzr@tangjimedical.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
( - ) Males or females with age between 18 and 65 years old;
( - ) Diagnosis of nonalcoholic fatty liver disease;
( - ) Proton density fat fraction measured by magnetic resonance imaging (MRI-PDFF) ≥8%;
( - ) BMI≥24;
Patients who understand the objective of the study; voluntarily participate in the study and have signed the informed consent form; and are able and willing to comply with all requirements, including follow up and evaluations.
Exclusion Criteria:
( - ) History of excessive alcohol consumption (alcohol consumption equivalent to ethanol > 30 g/d for males and > 20 g/d for females);
( - ) End-stage liver disease (e.g. hepatic cirrhosis or hepatic cancer) or other conditions which may lead to fatty liver;
( - ) Unable to cooperate to complete MR examination;
( - ) Subjects who have used any nonsteroidal anti-inflammatory drug or corticosteroid in the past month;
( - ) Patients with iron deficiency or iron deficiency anemia;
( - ) ALT or AST increased to 8 × upper limit of normal (ULN), and bilirubin increased to 2×ULN;
( - ) Patients with coagulation disorder or haemorrhagic diathesis (platelets <100×109/L);
( - ) Patients with duodenal ulcer, or previous or existing pancreatitis;
( - ) History of liver abscess;
( - ) History of gallstones (symptomatic or presenting of any stone with a diameter greater than 20mm);
( - ) Patients with gastrointestinal hemorrhage or potential hemorrhage;
( - ) Gastrointestinal tract anomalies, such as gastrointestinal tract atresia or any or other conditions that would result in failed placement in the gastrointestinal tract;
( - ) Patients with history of intestinal obstruction or related disease in the past year;
( - ) Drug abusers or patients with uncontrollable psychiatric disorders;
( - ) Patients with any contraindication to endoscopy based on the investigator's judgment;
( - ) Pregnancy or lactating women;
( - ) Patients who are participating in any other drug or medical device clinical study;
( - ) Patients with any other conditions evaluated by the investigators as unsuitable for participating in the trial;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A single arm study, only investigational product
To evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
|
This study includes 3 phases; screening period, procedural period, and a follow-up period.
Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0).
Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months.
In total subject participation will last for approximately 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of MRI-PDFF
Time Frame: 24 weeks after device implantation procedure(Visit 7)
|
Changes of MRI-PDFF at device retrieval
|
24 weeks after device implantation procedure(Visit 7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of MRI-PDFF
Time Frame: 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of MRI-PDFF at 12 and 24 weeks after device retrieval
|
12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of liver stiffness measurement (LSM)
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of liver stiffness measurement (LSM) at device retrieval, and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of liver inflammation/injury indicators (ATL, ASL, GGT, ALP, TBil, and DBil)
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of liver inflammation/injury indicators (ATL, ASL, GGT, ALP, TBil, and DBil) at device retrieval, and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of blood glucose indicators (fasting insulin, fasting blood glucose, fasting C-peptide, and insulin resistance [e.g. HOMA-IR])
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of blood glucose indicators (fasting insulin, fasting blood glucose, fasting C-peptide, and insulin resistance [e.g.
HOMA-IR]) at device retrieval, and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of blood lipids indicators, including triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, and lipoprotein (a)
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of blood lipids indicators, including triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, and lipoprotein (a), at device retrieval, and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of hepatic fibrosis indicators (PIIINP, Fibro Test/Fibro Sure, ELF, and NFS)
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Changes of hepatic fibrosis indicators (PIIINP, Fibro Test/Fibro Sure, ELF, and NFS) at device retrieval, and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Percent changes of body weight and changes of BMI
Time Frame: 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Percent changes of body weight and changes of BMI at device retrieval and 12 and 24 weeks after device retrieval
|
24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
|
Histological changes
Time Frame: 24 weeks after the implantation procedure (Visit 7)
|
Histological changes at device retrieval
|
24 weeks after the implantation procedure (Visit 7)
|
Evaluation on the usability of the device
Time Frame: 4 weeks after the implantation procedure (Visit 4) 、12 weeks after the implantation procedure (Visit 5)and 18 weeks after the implantation procedure (Visit 6)
|
Use abdominal X-ray evaluate Device implantation status
|
4 weeks after the implantation procedure (Visit 4) 、12 weeks after the implantation procedure (Visit 5)and 18 weeks after the implantation procedure (Visit 6)
|
Collaborators and Investigators
Investigators
- Principal Investigator: LunGen Lu, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Principal Investigator: Baiwen Li, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HZTJ03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Fatty Liver Disease
-
Columbia UniversityThorne Research Inc.WithdrawnNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver Disease
-
University of AarhusCompletedNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver DiseaseDenmark
-
Merck Sharp & Dohme LLCRecruitingNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, NonalcoholicCanada, United States, Puerto Rico, Israel, Japan, Korea, Republic of, Taiwan, Spain, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey
-
Columbia UniversityPfizerWithdrawnNASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
-
AdventHealth Translational Research InstituteCompletedNASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
AstraZenecaCompletedNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, NonalcoholicUnited States
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Assistance Publique - Hôpitaux de ParisCompletedNonalcoholic Fatty Liver Disease (NAFLD)France
-
Massachusetts General HospitalCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
Clinical Trials on Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
-
Paulo Reis Esselin de MeloHospital Estadual Geral de Goiânia Dr. Alberto RassiUnknown
-
Hangzhou Tangji Medical Technology Co., Ltd.Not yet recruiting
-
KAT General HospitalUnknown
-
Hadassah Medical OrganizationUnknownPerceptual Disorders | Cerebrovascular AccidentIsrael
-
Centre hospitalier de l'Université de Montréal...WithdrawnRuptured Aneurysm of Intracranial ArteryCanada
-
Pontificia Universidad Catolica de ChileUnknown
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States
-
Sohag UniversityNot yet recruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted